Patients With Brain Metastases From HER2-positive Breast Cancer
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the optimal sequences of combined trastuzumab
emtansine (T-DM1) and whole-brain radiotherapy in patients presenting brain metastases from
HER2-positive breast cancer in terms of acute toxicities and blood/cerebrospinal fluid T-DM1
pharmacokinetics.